The doctrine of equivalents in the medtech arena
The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.
- Five core IP legal principles in life sciences 09-07-2020
- Lanham Act: brand owners’ current weapon of choice 11-06-2020
- Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020
- Why things could get ugly over COVID-19 patents 30-04-2020
- COVID-19: patent procurement and licensing 31-03-2020
Latest americas news
Nevro escalates patent dispute with Boston Scientific
25-02-2021
Medical device maker Nevro has hit competitor Boston Scientific with a lawsuit for allegedly infringing patents that cover a spinal cord stimulation technology.